Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Rheumatology
•
Lupus nephritis
•
Systemic lupus erythematosus
•
Nephrology
Where do you introduce SGLT2 and GLP1 medications in the sequence of treatments for patients with lupus nephritis?
Related Questions
Should HCQ be continued in an asymptomatic SLE patient who has received renal transplant?
What factors do you consider when advising a patient with lupus nephritis on the safety of becoming pregnant?
Would you proceed with renal transplant in a patient with lupus nephritis who has progressed to ESRD and is clinically stable, but has persistently elevated dsDNA and low complements despite appropriate doses of hydroxychloroquine and mycophenolate?
What steroid regimen do you typically use for induction therapy in patients with lupus nephritis?
How would you approach a patient with class III and V lupus nephritis, already on HCQ, MMF, voclosporin and losartan, but has continued proteinuria not yet attaining complete renal response?
What do you feel are the potential barriers to widespread use of obinutuzumab in proliferative lupus nephritis?
What factors do you weigh most heavily when choosing between belimumab and voclosporin as part of a triple therapy regimen for newly diagnosed class IV LN?
How do you treat a patient with new class V lupus nephritis and recent hx of breast cancer on tamoxifen?
Are there instances when you consider rituximab first line in a patient with class V LN?
How would you approach potentially tapering maintenance mycophenolate mofetil in a patient with a history of class IV LN that has been in remission for >5 years?
